Acadia Pharma (ACAD) Halted Ahead of FDA PDAC Review of NUPLAZID

Needham & Company Remains Bullish on Acadia Pharma (ACAD) Following Positive FDA Vote on Nuplazid

Needham & Company reiterated a Buy rating and $49.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) following a vote by the FDA Psychopharmacologic Drugs Advisory Committee in favor of Nuplazid approval for treatment of Parkinson's Disease Psychosis. Committee members generally viewed Nuplazid as effective, with a few... More

Acadia Pharma (ACAD) Resumes Trading at 5:45 PM ET

Acadia Pharma (NASDAQ: ACAD) Resumes Trading at 5:45 PM ET

Acadia Pharma (ACAD) Announces Favorable FDA Panel Vote on NUPLAZID for the Treatment of Psychosis Associated with Parkinson's Disease

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12 to 2 that the benefits of NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinsons disease outweigh the risks of... More

Acadia Pharma (ACAD) wins FDA panel backing for Nuplazid - Bloomberg

Acadia Pharma (NASDAQ: ACAD) wins FDA panel backing for Nuplazid, according to Bloomberg.

Acadia Pharma's (ACAD) NUPLAZID Seen Effective in Parkinson's - FDA Panel

Acadia Pharma (NASDAQ: ACAD) received a positive FDA panel vote for pimavanserin in treating at least one disease. The following question was posed Tuesday:

1. VOTE: Has Acadia provided substantial evidence of effectiveness for NUPLAZID (pimavanserin) for the treatment of psychosis w/ PD?

12 panelists voted 'yes,' while 2 voted 'no.'

Acadia Pharma (ACAD) Said Facing 'Tough' Nuplazid Efficacy Questions from FDA Panel

Acadia Pharma (NASDAQ: ACAD) is said to be facing tough questions on the efficacy of Nuplazid. The following was posted by pharma-watcher Adam Feuerstein to Twitter on Tuesday:

... More

Acadia Pharma (ACAD) trading halted with news pending

Acadia Pharma (NASDAQ: ACAD) trading halted with news pending.

Acadia Pharma's (ACAD) Buy Rating Reiterated at H.C. Wainwright Ahead of Nuplazid's Adcom Meeting

H.C. Wainwright reiterated a Buy rating on Acadia Pharmaceuticals (NASDAQ: ACAD) with a price target of $50. Comments follow the release of FDA briefing documents for tomorrow's Nuplazid FDA adcom panel. Analyst Andrew S. Fein said he remains confident that clinical benefits outweigh risks.

"As anticipated, the discussion will center on clinical meaningfulness of the 3-point improvement on SAPS-PD and risk/reward in light of safety signals, including potential... More

Leerink Affirms ACADIA Pharma (ACAD) at 'Outperform'; Pimavanserin Briefing Docs More Crticial than Expected

Leerink affirms ACADIA Pharma (Nasdaq: ACAD) with an Outperform rating and $40 price target after the FDA Psychopharmacologic Drugs Advisory Committee released the pimavanserin briefing documents last Friday.

Analyst... More

Acadia Pharma (ACAD) Shares Active Ahead of NUPLAZID FDA Panel

Acadia Pharma (NASDAQ: ACAD) shares advanced pre-market after the FDA posted briefing documents ahead of its NUPLAZID panel on March 29. The documents are embedded below: